Company ProfilePremium

Ontex

Company Profile Analysis

Ticker: ONTEX.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ontex - Healthcare showcase

Year Founded & Workforce

1979

5,000 Employees

Industry

Healthcare
Ontex logo

Ontex Employee Contacts

160 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Ontex Overview

Ontex is a mid-sized European manufacturer of disposable personal hygiene products — adult incontinence, baby diapers and pants, and feminine care — sold predominantly under retailers' own labels and to healthcare channels, with a small portfolio of owned healthcare brands. After a four-year portfolio clean-up that sold all Emerging Markets operations (Mexico, Algeria, Pakistan, Brazil, Turkey), the group now generates ~€1.74bn of revenue from Europe and North America. Adult care has become the largest category (~47% of revenue in FY2025) and the designated growth pillar, while baby care — historically the core — is under structural pressure from falling birth rates, A-brand promotional intensity and retailer-brand share loss. The company is in a second-phase turnaround under CEO Laurent Nielly (since January 2026): a €240m "Focus to Value" savings programme, a profitability-first reset in North America, €144m of impairments, and a new CFO. With leverage at ~3.2x, bonds trading near 87% of par and Russia (≈5% of revenue) placed under Kremlin interim administration in October 2026, Ontex is a stressed small-cap equity whose value hinges on execution.


Company's own description

Ontex describes itself (H1 2026 press release, Jul 2026) as a leading international developer and producer of baby care, feminine care and adult care products, serving both retailers and healthcare, primarily in Europe and North America. Its corporate website adds that it partners with retailers and healthcare providers and is trusted by over 35 million people (ontex.com, 2026).

What the company does

Ontex designs, develops and manufactures absorbent hygiene products (AHPs) on high-speed converting lines that combine fluff pulp, superabsorbent polymer (SAP), nonwovens, films, elastics and adhesives. Its three categories are:

Adult care (incontinence): light incontinence pads, medium/heavy incontinence briefs (all-in-ones), pull-up pants, underpads and related products, sold to (a) healthcare channels — hospitals, nursing homes, home-care distributors and reimbursed tender systems in several European countries — and (b) retail (retailer-brand pads and pants). Adult care revenue was €814.1m in FY2025 (+1.6% LFL).

Baby care: baby diapers (tape), baby pants (pull-ups) and, historically, wipes; sold mainly as retailer brands across Europe and North America and as contract manufacturing for third parties in North America. Revenue €696.6m in FY2025 (−11% LFL).

Feminine care: sanitary towels, pantyliners and tampons, predominantly retailer brands in Europe plus contract manufacturing. Revenue €228.2m in FY2025 (−3.3% LFL).

(Source: Ontex FY2025 results press release, 12 Feb 2026.)

Business model and revenue model

DimensionCharacterization
Revenue model~100% product sales. No material service, subscription or licensing revenue disclosed
Channel model(1) Retailer brands (private label) — Ontex manufactures to retailer specification, often under multi-year supply contracts won through tenders; (2) Healthcare — owned brands and tender supply into institutional and reimbursed channels; (3) Contract manufacturing — production for other brand owners, around one-third of North American revenue (FY2025 results presentation)
Value chain positionMid-stream converter: buys commodity/semi-specialty inputs (pulp, SAP, polypropylene nonwovens, films) and converts them into finished goods; it does not own retail distribution (except healthcare logistics in some markets)
Pricing dynamicContracted or index-linked pricing with retailers; pass-through lags input-cost moves by one or more quarters (illustrated in H1 2026, when oil-derivative and freight costs rose faster than pricing actions)
Cost structureRaw materials are the largest cost block; fixed-cost absorption is significant, so volume swings drive outsized margin moves (FY2025: −5% volume drove a 2pp adj. EBITDA margin contraction)

Customers and end-markets

Customer types: large grocery and discount retailers and drugstore chains in Europe (named customers not disclosed), large US retailers (not named), healthcare providers and distributors, public tender bodies, and third-party brand owners (contract manufacturing).

End-markets: Western, Central and Eastern Europe (including Russia via a local subsidiary), North America (US, supplied from Stokesdale, North Carolina and Tijuana, Mexico — the latter USMCA-compliant), and selected overseas markets (including Australia via an Eastern Creek plant; "contract exits in other overseas markets" were cited in H1 2026).

Independent characterization

Ontex is a scale private-label converter in a category dominated by global A-brands (P&G, Kimberly-Clark, Essity). Its economic moat is limited to (i) manufacturing cost and quality at scale, (ii) long-standing retailer relationships, (iii) healthcare-channel know-how in adult incontinence, and (iv) innovation speed for retailer brands (e.g., baby pants, skin-health adult products). The business is structurally exposed to: raw-material price volatility; A-brand promotional cycles that compress the price gap with private label; demographic decline in baby care; and customer concentration. The post-divestment Ontex is cleaner but smaller, more levered relative to EBITDA, and now heavily dependent on European adult care for growth.

Strategy

Strategic evolution

Dec 2021 strategy (Berrozpe): Refocus on partner/retailer brands and healthcare; exit branded emerging markets.

2022–2025 (Calvo Paz): Three-year transformation — divest Emerging Markets; cost transformation (~€70m/yr savings in 2023–2024); invest in capacity in North America and European adult care (2023–2025 investment phase); Belgian footprint optimization; refinancing.

2026 (Nielly): Strategic review (Jan–Jul 2026) leading to a "fundamental transformation" toward a "more focused, resilient, cash-generating and value-driven Ontex" (H1 2026 release).

The four strategic shifts (July 2026)

  1. Focus to Value productivity programme: Incremental €40m EBITDA by end-2028 on top of the previously committed €200m savings target, totalling €240m. Levers: production and logistics optimization, simplification, lean manufacturing, streamlined organization (>20% reduction of white-collar positions excluding manufacturing by end-2028). Restructuring cash costs €60–65m over 24 months (of which ~€20m in H2 2026).

  2. North America reset: Prioritize profitability over volume, adjust capacity and operational set-up, review the customer portfolio, explore partnership opportunities; return to sustainable cash generation on a right-sized asset base.

  3. Accelerate adult care growth in Europe: Adult care becomes the "cornerstone" of growth — capacity, innovation and go-to-market investment to grow ahead of market.

  4. Targeted approach in European baby and feminine care: Focus on markets, customers and segments with sustainable returns; simplify product and asset portfolio.

Other initiatives in the last 24 months

InitiativeDateDetailStatus
Emerging Markets exit2023–Nov 2025Mexico, Algeria, Pakistan, Brazil, Turkey soldCompleted
Belgian footprint optimizationJun 2024–early 2026Eeklo closure; Buggenhout CoE (~€40m capex); ~€60m restructuring costFinalized in H1 2026
RefinancingNov 2024–Jul 2025€270m RCF; €400m 2030 notes; €580m 2026 notes repaidCompleted
Adult care capacityStarted end-Q3 2025Additional adult care capacity in Europe; ramp-up a 2026 priorityRamping
Contract winsQ3 2025New contracts in Europe and North America (lower volumes than expected)Operational
Pricing actions2,026Pass-through of freight and oil-derivative inflationOngoing; impact building in H2 2026
Transformation Management OfficeJul 2026Governance for 100+ initiativesActive
SustainabilityOngoingEcoVadis Gold (2nd consecutive year, top 3%); CDP Supplier Engagement "A" (May 2026)Ongoing

Medium-term guidance

FY2026 (revised 30 Jul 2026): Adj. EBITDA €165–180m (−6% to +3% vs €176m); FCF €(25)–(10)m; leverage below 3.5x at year-end. Previously: adj. EBITDA ~+10%, positive FCF, leverage ≤3.0x.

Medium-term ambition: Management intends to share "financial mid-term ambition and the associated building blocks" in the coming months (H1 2026 release). No quantified medium-term targets are currently in force.

Not yet reflected: The 16 Oct 2026 loss of operational control in Russia (7–8% of adj. EBITDA) post-dates the guidance; an update is expected at Q3 results on 28 Oct 2026.

Products & Services

Ontex's revenue is predominantly retailer brands (products sold under retailers' labels) and healthcare supply; owned brands are concentrated in healthcare adult care. Pricing models are contractual/tender-based and not disclosed product by product. Detailed specifications are generally not publicly disclosed; entries below reflect public descriptions.

Adult care (FY2025 revenue €814.1m)

Product line / brandDescriptionTarget customerStatus / latestNotes
iD (Ontex healthcare brand)Full incontinence range: light pads, medium/heavy all-in-ones, pants, underpadsHealthcare institutions, home care, pharmacies (Europe)ActiveFlagship owned healthcare brand (prior knowledge; not re-verified in this cycle)
SerenityItalian adult incontinence/healthcare brandItalian healthcare & retailActive (acquired c. 2013–14)Status per prior knowledge
Lille / Lille HealthcareIncontinence products for institutional careHealthcare (France, other EU)ActivePrior knowledge
EuronGerman healthcare incontinence brandGerman healthcareActivePrior knowledge
Retailer-brand adult pants and padsLight/moderate incontinence pads and pull-up pantsEuropean and North American retailersActiveGrowth driven by new capacity started end-Q3 2025
Sensitive rangeIncontinence range designed to support better skin healthHealthcare and retailLaunched early 2026 (Ontex news, 2026)Specifications not disclosed
Medium/heavy incontinence (Buggenhout CoE)Briefs/all-in-ones produced at modernized Buggenhout siteHealthcare~€40m investment programme (2024–2026)Centre of excellence for R&D and production

Baby care (FY2025 revenue €696.6m)

Product line / brandDescriptionTarget customerStatusNotes
Retailer-brand baby diapers (tape)Full size range, multiple quality tiers (value to premium)European and North American retailersActive; volumes −12% in FY2025Core historical business
Retailer-brand baby pantsPull-up training/diaper pantsRetailersActive; double-digit growth in H1 2026Key outperformer
Contract manufacturing (North America)Diapers produced for third-party brand ownersBrand ownersDeclining (anticipated)~1/3 of NA revenue across categories
Moltex, Helen HarperOwned European baby brandsRetail, eco/value segmentsActive (per company descriptions)Listed among brands in Simply Wall St profile
Ontex DreamshieldsOwned baby brandRetailListed in third-party profileDetails not disclosed
Divested brandsBBTips, Chicolastic, Kiddies, BioBaby (Mexico, sold 2023); Pom Pom, Cremer, Sapeka, Mônica (Brazil, sold 2025); Canbebe (Turkey, sold 2025)—DivestedThird-party profiles may still list them

Feminine care (FY2025 revenue €228.2m)

Product line / brandDescriptionTarget customerStatusNotes
Retailer-brand towels, liners, tamponsFull feminine hygiene rangeEuropean retailersActiveGrew slightly ahead of retailer brands in Europe (H1 2026)
NAT, SilhouetteOwned feminine care brandsRetailListed in third-party profilesDetails not disclosed
Contract manufacturingFeminine products for brand ownersBrand ownersDeclining in 2026Main driver of −4% volume in H1 2026

Services

Ontex describes "our services" on its website (co-development, customer innovation showcases and supply-chain partnership for retailers). These are not separately monetized.

Financial Narrative

Basis: Continuing operations (Core Markets) unless noted. FY2021 figures are not available on a comparable continuing-operations basis in the sources reviewed and are left blank. FY2022 core revenue and adj. EBITDA are derived from the FY2023 release (revenue bridge start-point €1,672.2m; FY2023 core adj. EBITDA €174m stated as +67%).

Income statement: notes and sources

Sources: FY2023 release (Feb 2024), FY2024 release (19 Feb 2025), FY2025 release (12 Feb 2026). FY2022 adj. EBITDA = analyst derivation (€174m ÷ 1.67). Gross profit: not disclosed in the excerpts reviewed (Ontex presents an operating-expense format in its business review). Diluted EPS: not disclosed in excerpts reviewed.

Margins (%)

Revenue CAGR FY2022–FY2025 (continuing): ~1.8% (analyst calculation). FY2024 LFL growth +3.5%; FY2025 LFL −4.9% (headline). Discrepancy: the FY2025 release summary bullet states a "−9% like-for-like decrease" while the headline and business review state −4.9% LFL; reported change (€1,860m → €1,762m) is −5.3%, consistent with −4.9% LFL.

Quarterly trajectory: notes and sources

Sources: quarterly releases. Q1 2025 restated adj. EBITDA €50.5m (Q1 2026 bridge); Q1 2026 adj. EBITDA €38.6m derived from H1 €78.1m less Q2 €39.5m. Discrepancy: the Q1 2026 bridge in the press release shows €38.8m; an earnings-call summary (Investing.com) cites "EUR 30 million" and "9.1% margin" — the €30m figure appears to be a transcription error; the margin (9.1%) is consistent with ~€38.6–38.8m.

Balance sheet and leverage

H1 2026 (30 June 2026): gross debt €619.0m; cash €79.1m; net debt €539.8m (incl. leases ~€146m); NWC €77.3m (4.5% of revenue); leverage 3.22x; liquidity €279m (cash + 75% undrawn of €270m RCF); off-balance-sheet factoring €187m (H1 2026 release).

Sources: FY2023 release (leverage 6.4x at end-2022), FY2024 earnings-call summary (gross debt €834m → €736m; liquidity €322m → €370m), FY2025 release. Total assets, equity, goodwill & intangibles, short/long debt split: not disclosed in sources reviewed (refer to 2025 Annual Report balance sheet). Goodwill impairment of €51m in North America (H1 2026) indicates material residual goodwill.

Debt composition (latest): €400m 5.25% senior unsecured notes due 15 April 2030 (semi-annual coupon); €270m RCF (signed Nov 2024, 5-year, ~25% drawn at June 2026); leases ~€146m; other facilities. The €580m 2026 notes were fully repaid in 2025.

Cash flow

H1 2026: capex €(29.2)m (3.4% of revenue), FCF €6.6m vs €(40.3)m in H1 2025; restructuring cash-out €(11)m; financing cash-out €(20)m. FY2026 FCF guided at €(25)–(10)m. Buyback: 1.5m shares (~€10m cash in 2025 per Q1 2025 presentation). Operating cash flow on a statutory basis: not disclosed in excerpts reviewed.

Ratios

ROE, ROA, ROIC, current ratio, debt/equity, asset turnover and cash conversion cycle: not computed — balance-sheet totals not disclosed in sources reviewed. Qualitatively: ROE was negative in FY2025 (net loss €173.5m) and will be negative in FY2026 (H1 loss €143.0m).

Commentary on trends, inflections and drivers

FY2022 trough: Input-cost inflation (pulp, SAP, energy, freight) crushed margins; core adj. EBITDA margin fell to ~6.2% and Total Group leverage hit 6.4x.

FY2023–FY2024 recovery: A cost transformation programme delivered €72m of savings in 2023 and ~€70m in 2024, reducing the operating cost base ~5% per year; volumes grew ~6% in 2024 (NA double-digit baby growth, adult care, baby pants). Adj. EBITDA rose from €104m to €223m; leverage fell to 2.46x with Mexico proceeds.

FY2025 inflection down: A −5% volume shock (baby −12%), customer destocking, supply-chain disruptions (Q2) and A-brand promotions cut adj. EBITDA 21% to €176m. Non-cash CTA recycling on Brazil and Turkey disposals drove a €190m loss from discontinued operations, resulting in a €173.5m net loss. Leverage rose to 3.29x despite €131m net divestment proceeds.

H1 2026: Revenue stabilized sequentially (Q2 flat YoY), adj. EBITDA margin recovered to 9.2% in Q2, FCF turned positive, but €144m impairments produced a €143m loss. Input-cost inflation from the Middle East crisis (freight from March, oil derivatives from June) forced a guidance cut to €165–180m.

Structural read: Margin volatility is driven mostly by volume (fixed-cost absorption) and the lag of price pass-through. The 2023–2024 margin recovery owed more to cost-out than to commercial strength, and savings have been largely consumed by inflation and volume loss since.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Category (EUR Mn)FY2023FY2024FY2025

Adult care revenue

736.4800.5814.1

Baby care revenue

790.0793.4696.6

Feminine care revenue

241.3236.6228.2

Sum of categories

1,767.71,830.51,738.9

Group revenue as reported

1,794.71,860.01,762.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

Category metric (%)FY2023FY2024FY2025

Adult care LFL growth

—9.01.6

Baby care LFL growth

—-0.1-11.0

Feminine care LFL growth

—-2.5-3.3

Adult care share of category revenue

41.743.746.8

Baby care share of category revenue

44.743.340.1

Feminine care share of category revenue

13.612.913.1

Revenue by Segment (Half-Yearly)

Category H1 (EUR Mn)H1 2025H1 2026

Adult care revenue

406.1410.0

Baby care revenue

351.9328.0

Feminine care revenue

114.0106.7

Group revenue

880.3854.8

Income Statement and Per-Share Data

Metric (EUR Mn)FY2021FY2022FY2023FY2024FY2025

Revenue (continuing)

—1,672.21,794.71,860.01,762.0

Adj. EBITDA (continuing)

—104.2174.0222.6175.6

Total Group adj. EBITDA (incl. discontinued)

—135.7223.3——

Depreciation and amortization

———74.177.5

Adj. EBIT (analyst calc.)

———148.598.1

EBITDA adjustments (one-offs)

———-72.7-19.1

Operating profit (continuing)

———76.079.0

Net finance cost

———-51.4-51.1

Adj. profit from continuing operations

———75.830.7

Profit from continuing operations

———20.916.6

Loss from discontinued operations

———-10.7-190.1

Profit/(loss) for the period

———10.3-173.5

Basic EPS (EUR)

———0.13-2.16

Dividend per share (EUR)

00000

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025

Adj. EBITDA margin

6.29.712.010.0

Adj. EBIT margin

——8.05.6

Operating margin

——4.14.5

Net margin (total group)

——0.6-9.8

Income Statement and Margin Analysis (%)

Quarter metric (EUR Mn)Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue

450.6429.7445.4436.0426.3428.5

Adj. EBITDA

50.535.750.839.038.639.5

Adj. EBITDA margin (%)

11.28.311.48.99.19.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Liquidity & Coverage Ratios and Financial Ratios (x)

Balance sheet (EUR Mn)FY2022FY2023FY2024FY2025

Gross financial debt

—834.0736.3647.4

Net financial debt

—665.0612.0577.0

Net working capital

——117.589.0

Net debt / adj. EBITDA (x)

6.43.252.463.29

Available liquidity

—322.0370.0—

Cash flow (EUR Mn)

Cash flow (EUR Mn)FY2021FY2022FY2023FY2024FY2025

Capex

———-112.4-81.1

Free cash flow (company definition, incl. interest)

———47.9-25.1

Share buybacks

————-10.0

Dividends paid

00000

Financial Ratios (x) and Margin Analysis (%)

RatioFY2022FY2023FY2024FY2025

Net debt / adj. EBITDA (x)

6.43.252.463.29

Adj. EBITDA / net finance cost (x)

——4.33.4

Capex / revenue (%)

——6.04.6

NWC / revenue (%)

——5.35.0

Region (As Available) Overview

Region (as available)Disclosure

Europe

Majority of revenue; adult care healthcare channel and retailer brands; not quantified in sources reviewed

North America

Not quantified in sources reviewed; contract manufacturing ≈ one-third of NA revenue (FY2025 presentation); NA retailer-brand baby volumes grew on contract gains through 2025–H1 2026

Russia

~5% of group revenue; 7–8% of adj. EBITDA (Ontex, 16 Oct 2026) — implied ~€87m revenue on LTM basis (analyst calc.)

Emerging Markets (discontinued, now divested)

Mexico ~€360m sales (2021); Turkey ~€90m sales (2024)

Region revenue (EUR Mn)

Region revenue (EUR Mn)FY2025

Russia (approx., ~5% of revenue)

88

Share Price

Price point (EUR)Oct 2021Oct 2023Oct 2025Jul 2026Oct 2026

Ontex share price (approx.)

9.06.96.22.251.81

Return

ReturnApprox. %

1-year

-70

3-year

-74

5-year

-80

Valuation Snapshot

MultipleValueBasis

Market cap

~€149m

€1.81 × ~82.4m shares

Enterprise value

~€689m

  • net debt €539.8m (June 2026, incl. leases); excludes €187m factoring

EV / LTM adj. EBITDA

~4.1x

LTM adj. EBITDA €167.5m (FY2025 €175.6m − H1 2025 €86.2m + H1 2026 €78.1m)

EV / FY2026E adj. EBITDA (guidance midpoint €172.5m)

~4.0x

Pre-Russia guidance

EV / LTM sales

~0.40x

LTM revenue ~€1,736m

P/B

Not computed

—

Pro forma leverage ex-Russia (illustrative)

~3.5x

€540m ÷ (€167.5m − ~€12.5m) — analyst illustration

Analyst Ratings & Targets

DateActionTarget (EUR)Source

21 Jan 2026

Downgrade to Sell

4.70 (from 6.30)

Investing.com

20 Feb 2026

Hold maintained

4.90 (from 5.10)

Investing.com

9 Apr 2026

Hold maintained

3.80 (from 4.90)

Investing.com

21 May 2026

Hold maintained

3.30 (from 3.80)

Investing.com

Jul 2026

Consensus average

4.02 (range 3.20–4.70)

Investing.com (pre-H1 results)

Capital Markets

ItemDetail

Fitch

Not rated (no rating identified)

Senior notes

€400m 5.25% due 15 Apr 2030; NC2 call schedule; 101% change-of-control put; issued 3 Apr 2025

Bond trading

~86.7–87.0% of par; YTM ~9.8–10.0% (DivvyDiary, Oct 2026)

RCF

€270m, 5-year (signed Nov 2024); ~25% drawn at June 2026

Debt Maturity Profile

Maturity (EUR Mn)20262027202820292030

Senior notes

0000400

RCF commitment (maturity ~2029)

0002700

Analyst Conclusions

Management guidance (as of 30 Jul 2026)

  • Adj. EBITDA €165–180m (vs €176m in FY2025), with H2 margin improvement from pricing and productivity.

  • Revenue largely stable.

  • FCF €(25)–(10)m.

  • Leverage below 3.5x at year-end 2026.

  • Mid-term ambition to be communicated in "the coming months."

Consensus growth expectations

Average 12-month price target was ~€4.02 in July 2026 (pre-H1), more than double the current price — implying consensus estimates are lagging the latest developments.

Bull case

  1. Self-help is large relative to the equity: €240m of planned savings by 2028 versus ~€168m LTM EBITDA and a ~€149m market cap; even partial net retention could re-rate the equity sharply at ~4x EV/EBITDA.

  2. Adult care becomes the growth engine: The category is already ~47% of revenue and still growing despite weak overall markets; new capacity is ramping.

  3. Optionality from anchor shareholders: GBL and ENA (~35%) plus a Board Strategy Committee create the conditions for a strategic transaction, NA partnership or take-private at a premium.

Bear case

  1. Leverage trap: Removing Russia's EBITDA pushes illustrative leverage toward ~3.5x before restructuring cash costs of €60–65m and negative FCF in 2026; bonds at ~10% YTM signal refinancing risk.

  2. Structural baby care decline: Baby revenue fell 12% in FY2025; A-brands keep promoting, and NA contract manufacturing is rolling off.

  3. Credibility deficit: Three guidance cuts in 12 months, two CEOs and two CFOs in 2026; savings have repeatedly been absorbed by inflation and volume loss.

Catalysts and monitorables (next 12 months)

Date / windowCatalystWhat to watch
28 Oct 2026Q3 2026 resultsRussia accounting treatment (deconsolidation/impairment), revised guidance, Q3 pricing pass-through
H2 2026Mid-term targetsMargin and leverage targets; Focus to Value phasing
OngoingRussiaAny reversal of interim administration; legal recourse; insurance
OngoingRating agenciesMoody's/S&P actions after Russia event
2026–2027NA resetCapacity cuts, customer exits, partnership announcements
Feb 2027FY2026 results (11 Feb 2027)Year-end leverage vs <3.5x commitment; FCF
OngoingInput costsOil derivatives, pulp, SAP and freight trends
OngoingShareholder registerGBL/ENA moves; new 3%+ holders

Analyst verdict

Ontex enters the final quarter of 2026 as a deeply discounted, highly levered turnaround whose investment case has shifted from "portfolio clean-up complete, margin recovery under way" (early 2025) to "survive, shrink to profitability, and prove cash generation" (late 2026). The divestment programme achieved its strategic goal — a simpler Europe and North America business with adult care as the largest category — but did so while the remaining core weakened: baby care revenue fell by €97m in a single year, North American investments required €106m of impairments, and adj. EBITDA dropped from €223m to an expected €165–180m. The Russian interim administration compounds the problem by removing operational control over a unit delivering 7–8% of adj. EBITDA at a moment when every euro of EBITDA matters for the leverage ratio.

On the other side of the ledger, the equity now trades at roughly 4x EV/EBITDA with a market value under €150m, against a credible, quantified productivity plan (€240m by 2028), positive H1 2026 free cash flow, improving working capital, no bond maturity until 2030, and a demographically supported adult care franchise. New leadership — an internal CEO who ran Europe and an external CFO with private-label transformation experience — has acted decisively on costs and asset impairments rather than defending past investments.

Our verdict is that Ontex is a high-risk, event-driven special situation rather than a fundamental compounder. The asymmetry is real but conditional on three proofs within 12 months: (1) H2 2026 margin recovery from pricing; (2) a transparent treatment of Russia without covenant or rating stress; and (3) visible Focus to Value savings dropping through to EBITDA. Failure on any one keeps the balance sheet the binding constraint. Given anchor-shareholder concentration, a strategic outcome is a plausible exit route. Investors should size positions accordingly and treat the 28 October Q3 release as the next decisive data point.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / background

Laurent Nielly

Chief Executive Officer

CEO since 13 Jan 2026; President Europe Division 2021–2025; previously led Ontex Brazil

25+ years in Europe, US and Latin America; P&G, McKinsey & Company, PepsiCo, Coty; began in finance and strategy

Stéphane Re

Group CFO

Since 14 Sep 2026

Group CFO, Partner in Pet Food (CVC/Cinven-owned private label pet food); Group CFO Thai Union Europe/MW Brands 2014–2021; Swiss national

Annick De Poorter

Chief Innovation & Sustainability Officer

——

Jonas Deroo

Chief HR & Legal Officer

——

Marco Querzoli

Chief Supply Chain Officer

——

New President Europe

President Europe Division

——

New Head of North America

President North America

——

Geoffroy Raskin

Head of Investor Relations (not EMC)

——

“—” = not publicly disclosed.

Board of Directors

DirectorRoleIndependence / affiliationNotes

Hans Van Bylen

Chairman

Independent

Chair since at least Dec 2020; former Henkel CEO (prior knowledge)

Ebrahim Attarzadeh

Non-executive director

——

Inge Boets

Independent director

Independent

—

Michael Bredael

Non-executive director

Shareholder-affiliated (GBL, prior knowledge)

—

Lorenzo Grabau

Non-executive director

Co-opted Jan 2026; ratification at May 2026 AGM (all resolutions approved)

Former President & CEO of Kinnevik AB; capital-markets and transformation expertise

Jesper Hojer

Former director

Resigned (announced Jan 2026)

Former CEO Lidl International

Board & Management Changes

DateChangeContext

11 Dec 2025

Nielly named CEO-designate (effective May 2026)

Alongside second FY2025 guidance cut

13 Jan 2026

Nielly CEO immediately; strategic review; Grabau co-opted

Board signalled "all avenues" for value creation

30 Jul 2026

New CFO (Re), new heads of North America and Europe, TMO created

Strategic review conclusions

14 Sep 2026

Re starts; Peeters departs

—

Major Shareholders

ShareholderStake (%)Source / date

Groupe Bruxelles Lambert (GBL)

~20.0–20.5

Octus (Mar 2025); Simply Wall St

ENA Investment Capital LLP

~15.1–15.4

Octus (Mar 2025); Simply Wall St

Brandes Investment Partners

~10.3

Simply Wall St

The Pamajugo Irrevocable Trust

~3.4–3.6

Octus; Simply Wall St

DNCA Finance / Natixis

~3.0–3.1

Octus; Simply Wall St

Black Creek Investment Management

~3.0

Simply Wall St

Vanguard Group

~2.9

Simply Wall St

Joannes G.H.M. Niessen / Mont Cervin SARL

Below 3% since 23 Mar 2026 (was ~3.1%)

Ontex transparency notice, Mar 2026

Goldman Sachs Group

Oscillating around 3% (mostly equivalent financial instruments; e.g., 2.86% on 3 Sep 2026)

Ontex transparency notices, Jun–Sep 2026

Dimensional Fund Advisors

~2.1

Simply Wall St

Competitive Landscape

Key Competitors

CompetitorCategories overlapping OntexModelRelative positioning vs Ontex

Procter & Gamble (Pampers, Always, Discreet)

Baby, feminine, adult

Global A-brand

Price leader and promotional aggressor; A-brand promotions cited as cause of retailer-brand share loss in 2025

Kimberly-Clark (Huggies, Depend, Kotex)

Baby, adult, feminine

Global A-brand

Major in NA; international personal care being combined with Suzano in a JV (announced 2025; prior knowledge)

Essity (TENA, Libero, Libresse, Bodyform)

Adult (global leader), baby, feminine

A-brand + healthcare

Direct and strongest competitor in European adult incontinence healthcare

Drylock Technologies (Belgium, private)

Baby, adult

Private label / innovation

Closest private-label peer in Europe

First Quality Enterprises (US, private)

Baby, adult, feminine

US private label

Main North American retailer-brand competitor

Paul Hartmann (MoliCare)

Adult

Healthcare brand

Competes in healthcare incontinence (Germany/Europe)

Abena (Denmark, private)

Adult

Healthcare brand/distributor

Competes in healthcare tenders

Fater (P&G/Angelini JV, Italy)

Baby, feminine, adult

Branded

Strong in Italy and Southern Europe

Attends Healthcare Products

Adult

Healthcare brand

Europe/NA healthcare

Albaad

Feminine

Private label/contract

Feminine care private label

Unicharm

Baby, adult, feminine

A-brand (Asia-centric)

Limited European presence

Peer Comparison FY2025

MetricOntexEssityKimberly-ClarkProcter & Gamble

Latest FY revenue

€1.76bn (FY2025)

~SEK 145bn (FY2024, approx.)

~$20bn (FY2024, approx.)

~$84bn (FY June 2025, approx.)

Revenue growth (organic/LFL)

−4.9% (FY2025)

———

EBITDA margin

10.0% adj. (FY2025)

———

Company Snapshot

5,000

Employees

1979

Founded

Erembodegem, Belgium

Headquarters

SWOT Analysis

Strengths

  • Adult care leadership: Adult care revenue rose from €736.4m (FY2023) to €814.1m (FY2025) and grew volumes even in the weak H1 2026 (+1%), giving Ontex exposure to a demographically supported category.
  • Proven cost-out capability: The cost transformation delivered €72m (2023) and ~€70m (2024) of savings, lifting the adj. EBITDA margin from ~6.2% (FY2022) to 12.0% (FY2024).
  • Portfolio simplified: All Emerging Markets businesses sold by Nov 2025, removing FX/hyperinflation volatility (e.g., ~€70m CTA losses on Turkey are now behind it).
  • Long-dated funding: No bond maturity until April 2030; €279m liquidity at June 2026.
  • Working-capital discipline: NWC fell to 4.5% of revenue (June 2026) from 5.3% (end-2024).
  • Tariff-insulated NA supply: Tijuana output is USMCA-compliant, minimizing direct US tariff impact (Q1 2025 release).
  • ESG credentials: EcoVadis Gold (top 3%, two consecutive years); CDP Supplier Engagement A (2026).

Weaknesses

  • Earnings volatility: Adj. EBITDA fell 21% in FY2025 on a 5% volume decline, revealing high operating leverage.
  • Leverage: 3.22x net debt/EBITDA (June 2026), with guidance only "below 3.5x" at end-2026, plus €187m off-balance-sheet factoring.
  • Baby care erosion: Baby revenue fell from €793.4m (FY2024) to €696.6m (FY2025), −11% LFL.
  • Negative FCF: FY2025 FCF €(25.1)m; FY2026 guided €(25)–(10)m.
  • North America under-returning: €51m NA goodwill impairment and €55m NA asset impairment (Jul 2026) acknowledge that the 2023–2025 investments did not yield expected returns.
  • Forecasting record: Guidance revised down in Jul 2025, Dec 2025 and Jul 2026.
  • Limited disclosure: No divisional revenue/profit split, reducing transparency.

Opportunities

  • Focus to Value: €240m cumulative savings by 2028 against a ~€170m EBITDA base — large relative upside if retained.
  • Pricing pass-through: H2 2026 margin improvement expected as pricing catches up with input costs.
  • Adult care capacity: New European capacity started end-Q3 2025; ramp-up in 2026–2027.
  • NA partnerships: Exploring partnerships to right-size NA assets and release capital.
  • Strategic optionality: ~35% held by GBL and ENA plus a Board Strategy Committee; equity value of ~€149m versus ~€690m EV could attract strategic or private-equity interest (speculative).
  • Baby pants growth: Double-digit growth in H1 2026 shows a format where Ontex outperforms.

Threats

  • Russia: Interim administration removes operational control of 7–8% of adj. EBITDA; potential deconsolidation or write-off.
  • Input cost inflation: Middle East crisis drove freight (from Mar 2026) and oil-derivative costs (from Jun 2026) higher.
  • A-brand promotions: Cited as amplifying retailer-brand demand declines in 2025.
  • Customer/contract churn: Contract exits in overseas markets and NA contract manufacturing decline (H1 2026).
  • Refinancing/credit risk: 2030 bonds trading ~87% of par (YTM ~10%) signal market concern; rating actions in Apr–May 2026.
  • Execution risk: >20% white-collar reduction and capacity cuts during a CFO transition.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Early Apr 2025Brazil divestment closed (~€99m preliminary net proceeds)Deleveraging; EM exit nearly complete
Apr 2025€580m 2026 notes tendered; €400m 2030 notes settled (issued 3 Apr 2025)Maturity extended to 2030
Mid-Apr 20251.5m share buyback completedLTI cover
30 Apr 2025Q1 2025: revenue €451m; adj. EBITDA €51m (11.2%); FY outlook confirmed (adj. EBITDA +4–7%)Last "clean" quarter
Jul 2025€580m notes remainder redeemedRefinancing complete
Jul 2025H1 pre-announcement: Q2 below expectations; FY adj. EBITDA guided €200–210m (from €232–238m)First 2025 profit warning
Jul/Aug 2025H1 2025: adj. EBITDA €86m (9.8%); net debt €552mBaby care weakness, supply disruption
30 Oct 2025Q3 2025: revenue €445m (−3.8% LFL); adj. EBITDA €51m (11.4%); outlook maintainedSequential recovery; new contracts and adult capacity start
3 Nov 2025Turkey sale to Dilek Grup closed (~€25m net)EM exit concluded
11 Dec 2025Guidance cut (baby care weakness in Oct–Nov); Nielly named CEO successorSecond profit warning; leadership change
13 Jan 2026Nielly CEO immediately; strategic review; Strategy Committee; Grabau co-optedBoard signals urgency
21 Jan 2026Broker downgrade to Sell (target €4.70 from €6.30)Sentiment deterioration (Investing.com)
12 Feb 2026FY2025: revenue €1,762m; adj. EBITDA €176m; net loss €(173.5)m; 2026 guidance adj. EBITDA ~+10%Reset year
12 Feb 2026EcoVadis Gold for 2nd consecutive year (top 3%)ESG credential
Feb–Mar 20262025 Annual Report "Building foundations for the future" publishedFiling
23 Mar 2026Niessen/Mont Cervin drop below 3%Shareholder exit
Mar 2026 onwardMiddle East crisis drives freight costs upInput cost headwind
21 Apr 2026Credit watch item
29 Apr 2026Q1 2026: revenue €426m (−4% LFL); adj. EBITDA ~€39m (9.1%); outlook maintainedSoft start as guided
5–6 May 2026AGM; all resolutions approved (incl. Grabau ratification)Governance
11 May 2026Credit watch item
20 May 2026CDP Supplier Engagement "A" score againESG
21 May 2026Broker maintains Hold, target cut to €3.30Sentiment
Jun 2026Oil-derivative raw material prices riseMargin pressure in H2
30 Jul 2026Strategic review outcome; €144m impairments; Focus to Value €240m; guidance cut to €165–180m; H1 loss €(143)m; new CFO namedMajor reset
Jun–Sep 2026Repeated Goldman Sachs 3% threshold crossings (derivatives)Trading/hedging activity
14 Sep 2026Stéphane Re starts as CFOLeadership
2 Oct 2026Shares hit €1.80 lowMarket stress
8 Oct 2026Q3 results date set (28 Oct)Calendar
15–16 Oct 2026Ontex Russia placed under state interim administration; shares hit all-time low €1.78Loss of ~7–8% of EBITDA control

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue (continuing) rose from EUR 1,672.2 Mn in FY2022 to EUR 1,762 Mn in FY2025.
Ontex — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2022FY2023FY2024FY2025
Revenue (continuing)1,672.21,794.71,8601,762

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.